Nephrocare Health Services
MainboardGMP is market estimated & subject to change. Not a guaranteed listing price.
Nephrocare Health Services IPO Issue Details
| Issue Price | ₹438-460 per equity share |
| Face Value | ₹2 Per Equity Share |
| Total Issue Size | 1,89,35,819 shares(aggregating up to ₹871.05 crore) |
| Fresh Share | N/A |
| Offer For Sale | N/A |
| Listing at | BSE, NSE |
| List Price | N/A |
| Listing Date | 2025-12-17 |
| Lead Manager | ICICI Securities Limited/nAmbit Pvt.LtdIIFL Capital Services Ltd.Nomura Financial Advisory & Securities (India) Pvt.Ltd. |
| Registrar | Kfin Technologies Limited |
Nephrocare Health Services IPO Live Subscription
Last Updated: 12 Dec, 13:42Total Subscription
14.08 x
Based on live data from BSE/NSE
Nephrocare Health Services IPO Subscription Analysis And Details
| Day / Date | QIB | NII (HNI) bNII (>10L) sNII (<10L) | Retail | Total |
|---|---|---|---|---|
| Shares Offered reserved quota | 0.00 x | 0.10 0.07 0.15 | 0.21 x | 0.13 x |
Day 110 Dec 2025 | 0.29 xx | 0.23 0.16 0.36 | 0.47 xx | 0.37 xx |
Day 211 Dec 2025 | 26.82 xx | 24.77 30.43 13.46 | 2.35 xx | 14.08 xx |
Total Applications
4,59,377
Retail Subscription
Profit Estimator
Calculate your potential listing gains
Investment Amount
₹14,368.00
Current GMP
+₹28.75
Estimated Profit
Investor Sentiment
Be the first to vote!
Nephrocare Health Services IPO Financial Scorecard
Nephrocare Health Services IPO Peer Comparison
Nephrocare Health Services IPO Financial Results
| Metric | 30-Sep-25 | 31-Mar-25 | 31-Mar-24 | 31-Mar-23 |
|---|---|---|---|---|
| Assets | 1193.68 | 996.46 | 806.02 | 666.23 |
| Revenue | 483.97 | 769.92 | 574.72 | 443.26 |
| Profit After Tax | 14.23 | 67.10 | 35.13 | -11.79 |
| Net Worth | 716.06 | 594.21 | 423.55 | 384.73 |
| Reserves & Surplus | 704.14 | 578.68 | 408.57 | 383.50 |
| Total Borrowing | 207.04 | 225.80 | 243.37 | 196.21 |
* In Cr.
IPO Timeline
IPO Open
10 Dec 2025
IPO Close
12 Dec 2025
Allotment
15 Dec 2025
Refunds
16 Dec 2025
Demat Credit
17 Dec 2025
Listing
17 Dec 2025
IPO Open
10 Dec 2025
IPO Close
12 Dec 2025
Allotment
15 Dec 2025
Refunds
16 Dec 2025
Demat Credit
17 Dec 2025
Listing
17 Dec 2025
Nephrocare Health Services IPO Lot Size & Application
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (Min) | 1 | 32 | ₹14,720 |
| Retail (Max) | 13 | 416 | ₹1,91,360 |
| S-HNI (Min) | 14 | 448 | ₹2,06,080 |
| S-HNI (Max) | 67 | 2144 | ₹9,86,240 |
| B-HNI (Min) | 68 | 2176 | ₹10,00,960 |
Nephrocare Health Services IPO About Company
Nephrocare Health Services Ltd, incorporated in the year 2010, is an end-to-end dialysis care provider through its wide network of clinics across India and select international markets. It offers services such as diagnosis, haemodialysis, home and mobile dialysis, and wellness programs, supported by an in-house pharmacy.
As of March 31, 2025, Nephrocare operated 490 clinics—447 in India and 43 across the Philippines, Uzbekistan, and Nepal. This includes the world’s largest dialysis clinic in Uzbekistan. In India, the company had a presence across 269 cities in 21 States and four Union Territories. Approximately 76.73% of its clinics were located in tier II and tier III cities, addressing a critical need in underserved regions.
In Fiscal 2025, Nephrocare treated 29,281 patients and performed more than 2.88 million dialysis treatments, amounting to approximately 10% of the country's total dialysis patient base. The number of dialysis machines operated by the company increased to 5,068 as of March 2025 from 4,714 in Fiscal 2024 and 3,662 in Fiscal 2023.
Nephrocare has formulated strategic alliances with leading hospital chains like Max Super Speciality Hospital, Fortis Escorts Hospitals, Care Hospitals, Wockhardt Hospitals, Paras Healthcare, The Calcutta Medical Research Institute, Jehangir Hospital, and Ruby Hall Clinic to operate in-house dialysis centers.
As of March 2025, the workforce consisted of 3,230 employees, including both medical and administrative staff working across its clinics and corporate office.
Nephrocare Health Services IPO Share Holding
Pre Issue
78.90%
Post Issue
71.49%
Promoters
Nephrocare Health Services IPO Where is the money going?
- 1
Capital expenditure by the Company for opening new dialysis clinics in India
- 2
Pre-payment, or scheduled repayment, in full or part, of certain borrowings availed by the Company
- 3
General corporate purposes
COMPANY
Nephrocare Health Services
5th Floor, D Block, iLabs Centre, Plot 18, Software Units Layout, Survey No. 64, Madhapur, Shaikpet, Hyderabad, Telangana, 500081
PHONE
+91 40 4240 8039
REGISTRAR
Kfin Technologies Limited
Common Questions
To decide on investing in Nephrocare Health Services, consider its financial health. The company reported a revenue of {"30-Sep-25": "483.97", "31-Mar-25": "769.92", "31-Mar-24": "574.72", "31-Mar-23": "443.26"} and a profit after tax of {"30-Sep-25": "14.23", "31-Mar-25": "67.10", "31-Mar-24": "35.13", "31-Mar-23": "-11.79"}. It has a P/E ratio of N/A and a RoNW of 13.19%%. Always review the RHP and consult a financial advisor before investing.
Based on the latest Grey Market Premium (GMP) of ₹0, the expected listing price is around ₹460 per share. This suggests a potential listing gain of approx 0%. (Note: GMP is volatile and not a guarantee).
The IPO opens for subscription on 10 Dec, 2025 and closes on 12 Dec, 2025. The allotment status will be finalized by 15 Dec, 2025, and listing is expected on 17 Dec, 2025.
Retail investors need to apply for a minimum of 1 lot (32 shares) which requires an investment of ₹14,720. For HNI investors, the minimum investment is 14 lots (448 shares) amounting to ₹2,06,080.
You can check the allotment status on the registrar's website (Kfin Technologies Limited) or via the BSE/NSE website once the allotment is finalized on 15 Dec, 2025.
The price band for Nephrocare Health Services IPO is set at ₹438 to ₹460 per share.
The minimum market lot (lot size) for Nephrocare Health Services IPO is 32 shares. Retail investors can apply for up to 13 lots (416 shares or ₹1,91,360).
The issue is divided into categories: Qualified Institutional Buyers (QIB) get N/A%, Non-Institutional Investors (NII/HNI) get N/A%, and Retail investors are allocated N/A% of the shares.